Linezolid

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 122-125

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DA 7157; DA 7218; DA 7867; ETHAMBUTOL; FENTHION; FLUOXETINE; IMIPRAMINE; ISONIAZID; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PAROXETINE; PNU 100480; PSEUDOEPHEDRINE; RIFAMPICIN; SERTRALINE; STREPTOMYCIN; TYRAMINE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ISOLATE; BINDING AFFINITY; BLURRED VISION; BONE MARROW SUPPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERANCE; ENTEROCOCCUS; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEADACHE; HOSPITAL INFECTION; HUMAN; LEUKOPENIA; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PLASMA PROTEIN BINDING; PNEUMONIA; PRIORITY JOURNAL; RAT; RESPIRATORY FAILURE; REVIEW; RNA TRANSLATION; SEPSIS; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STOMACH PH; THROMBOCYTOPENIA; URINARY EXCRETION;

ACETAMIDES; ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249112491     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70014-3     Document Type: Review

References (19)

1. Vera-Cabrera L., et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 50 (2006) 3170-3172
2. Vera-Cabrera L., et al. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria. Antimicrob Agents Chemother 50 (2006) 4027-4029
3. McKee E., et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50 (2006) 2042-2049
4. Erturan Z., and Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 26 (2005) 78-80
5. Tsiodras S., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
6. Herrero I., et al. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346 (2002) 867-869
7. Richter E., et al. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 51 (2007) 1534-1536
8. Acala L., et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47 (2003) 416-417
9. Tato M., et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 28 (2006) 75-78
10. Sood R., et al. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against My-cobacterium tuberculosis infected murine macrophages. Int J Antimicrob Agents 25 (2005) 464-468
11. Rodriguez J., et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53 (2004) 441-444
12. Cynamon M., et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 43 (1999) 1189-1191
13. Fortun J., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56 (2005) 180-185
14. Park I., et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 58 (2006) 701-704
15. Slatter J., et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32 (2002) 907-924
16. Dailey C., et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45 (2001) 2304-2308
17. Gee T., et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45 (2001) 1843-1846
18. Honeybourne D., et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51 (2003) 1431-1434
19. Hickey E., et al. Experimental model of reversible myelosuppression caused by short-term, high-dose oxazolidinone administration. Therapy 3 (2006) 521-526